Naproxen ER FDA guidance [Regulatives / Guidelines]

posted by sunny – 2014-04-17 02:07 (4445 d 16:35 ago) – Posting: # 12845
Views: 4,487

(edited on 2014-04-25 10:10)

Hi Helmut,

Thank you for sharing your thoughts on this topic. Coincidentally, I found a pending citizen petition related to BE criteria for Naprelan (extended release Naproxen). The petitioner did ask FDA to request partial AUCs. In checking the package insert, EC-Naprosyn (enteric coated Naproxen for delayed release) was not approved for acute pain as the release is delayed. I would like to know your opinion on this citizen petition.

http://www.regulations.gov/#!documentDetail;D=FDA-2014-P-0407-0001

Thanks,
Sunny


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Dr_Dan]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
161 visitors (0 registered, 161 guests [including 17 identified bots]).
Forum time: 18:42 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5